title: Long-term outcome of a phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients.
abstract: BACKGROUND
  Mismatched family donor and unrelated donor BM transplants are associated with a high risk of acute GvHD. White T-cell depletion is the best method to reduce risk of acute GvHD, there was a reluctance to use T-cell depletion in the mismatched setting because of increased risk of rejection and relapse. Partial T-cell depletion, by the panning of CDS and CD8 positive T cells may reduce complications related to GvHD without compromising outcomes.
  
  
  METHODS
  In a long-term follow-up of a Phase II study of partial T-cell depletion by panning for BM transplant, 32 recipients received transplants from a single-Ag (HLA A, B, or DR) mismatched family donor; or an HLA serologically-matched unrelated donor. Patients were studied for engraftment, GHD, relapse and survival.
  
  
  RESULTS
  30 (94%) of the patients marrow engrafted. The cumulative risk of Grade 2-4 acute GvHD was 62 - 9%; of Grade 3-4 GvHD, 11 - 6%. The 4-year cumulative risk of relapse was 18 - 8% and actuarial survival was 44 - 9%.
  
  
  CONCLUSIONS
  Partial T-cell depletion had a low rate of severe acute GvHD without compromising engrafment or relapse risk.
authors.affiliation: Department of Blood and Marrow Transplantation, MD Anderson Cancer Center; Houston, Texas, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Gajewski
authors.forename: S
authors.initials: S
authors.lastname: Nimer
authors.forename: R M
authors.initials: RM
authors.lastname: Saliba
authors.forename: M
authors.initials: M
authors.lastname: Thomas
authors.forename: D
authors.initials: D
authors.lastname: Przepiorka
authors.forename: S
authors.initials: S
authors.lastname: Giralt
authors.forename: K
authors.initials: K
authors.lastname: von Besien
authors.forename: R
authors.initials: R
authors.lastname: Mehra
authors.forename: B
authors.initials: B
authors.lastname: Andersson
authors.forename: K W
authors.initials: KW
authors.lastname: Chan
authors.forename: C
authors.initials: C
authors.lastname: Ippoliti
authors.forename: D
authors.initials: D
authors.lastname: Warkinten
authors.forename: S
authors.initials: S
authors.lastname: Feigs
authors.forename: M
authors.initials: M
authors.lastname: Territo
authors.forename: G
authors.initials: G
authors.lastname: Schiller
authors.forename: J
authors.initials: J
authors.lastname: Lebkowski
authors.forename: A M
authors.initials: AM
authors.lastname: Moseley
authors.forename: K
authors.initials: K
authors.lastname: Lloyd
authors.forename: M
authors.initials: M
authors.lastname: von Hoeff
authors.forename: T
authors.initials: T
authors.lastname: Okarma
authors.forename: R
authors.initials: R
authors.lastname: Champlin
mesh_terms: D000293:Adolescent; D000328:Adult; D001854:Bone Marrow Cells / Q000166:cytology; D016026:Bone Marrow Transplantation / Q000379:methods*; D018956:CD5 Antigens / Q000096:biosynthesis*; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control; D006648:Histocompatibility; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008297:Male; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D018956:CD5 Antigens